Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Beyond Five is an Australian charity supporting people affected by head and neck cancer. HNC is Australia’s 7th most common cancer and can affect a person’s mouth, tongue, skin or voice-box. HNC is not just caused by smoking and alcohol. It can be caused by the human papilloma virus and sometimes the cause is unknown. 5,000 people are diagnosed each year and 17,000 are living with HNC. There is no screening: Early detection is key.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. As an independent company, we plan in generations and focus on long-term success. Our goal is to improve the health and quality of life of patients and our focus is on diseases for which no satisfactory treatment option exists.
As a research-driven company, we actively collaborate with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.
Women with a lived experience of cancer are uniquely placed to help others. Counterpart connects, supports and informs women living with breast or a gynaecological cancer to live well. Highly-trained Peer Support Volunteers who have experienced cancer provide hope, understanding, and emotional and practical support.
Counterpart also provides a range of free programs including events, webinars and a library.
Counterpart is a service of Women’s Health Victoria and is supported by the Victorian Government.
Gilead’s mission is to advance patient care by developing therapeutics to treat life threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions in the areas of Haematology/Oncology (ZYDELIG® [idelalisib]), HIV, chronic hepatitis B, chronic hepatitis C and systemic fungal infections (AmBisome® [liposomal amphotericin B]).
Ipsen provides specialty medicines to Healthcare Professionals and their patients suffering from debilitating diseases.
At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals.
Ipsen is the Australian affiliate of a global R & D focused pharmaceutical company.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com.au
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies.
Mylan has a growing portfolio of Biosimilars, with one of the strongest pipelines in the industry. Biosimilars increase timely and affordable patient access to the latest treatments and help deliver a sustainable Pharmaceutical Benefits Scheme. Mylan’s investment in biosimilars is an exciting evolution in how we can treat Australian patients.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost saving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives. To find out more about Novartis in Australia visit www.novartis.com.au
Pfizer Oncology works collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners to further its extensive research and development program. We are committed to partnerships with professional and patient organisations that deliver benefits to patients including disease management tools, awareness of clinical trial options and access to new medicines. Working together, we strive to transform treatment by targeting the right drug for the right patient at the right time.
Rare Cancers Australia Ltd (RCA) is a charity whose purpose is to improve the lives and health outcomes of Australians living with rare and less common (RLC) cancers.
RCA has a number of key areas of focus: Creating a Patient Community, Advocacy, Patient Support Programs, Fundraising, Treatment & Research along with Early Diagnosis.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
The Cancer Nursing Research Group works with cancer clinicians and cancer consumers to develop new, and implement existing evidence, into practice. Our nurse-led work focuses on improving care experiences and outcomes for people affected by cancer and on equity of access to supportive care. Our research examines systems and models of care and focuses on complex cancer symptoms such as fatigue and cognitive decline. Research methodologies include mixed methods, co-design, health services research and implementation science.
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 9,200 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.
WCMICS is part of the Victorian Integrated Cancer Services; an improvement network funded by the Victorian Government. Our goal is to improve patient experiences and outcomes by connecting cancer care and driving best practice. We achieve this through
- Collaboration, working in partnership to understand unmet needs and drive improvements
- Facilitation, accelerating opportunities to expand reach of access to care
- Innovation, creating new ways to act and support changes that benefit the cancer community